Growth Hormone AxisIn StockGrowth Hormone Axis
Tesamorelin
Also known as: TH9507, GHRH(1-44) analog, Egrifta (parent drug)
Stabilized 44-amino-acid GHRH analog with an N-terminal hexenoyl modification; parent compound is FDA-approved for a specific indication.
Tesamorelin is a synthetic analog of full-length human GHRH (amino acids 1–44) with an N-terminal trans-3-hexenoic-acid modification that confers stability against DPP-IV proteolysis.
It is one of the most complex GHRH-family peptides in the research catalog, both chemically and in terms of its published research profile.Tesamorelin has been studied extensively in endocrinology research for its interaction with the GHRH receptor, downstream effects on IGF-1 dynamics, and metabolic-tissue research related to adipose biology.
The parent pharmaceutical product (Egrifta, Theratechnologies) is FDA-approved for a narrowly defined clinical indication; this catalog entry refers strictly to research-grade material for laboratory use.Due to synthesis complexity (44 amino acids with the hexenoyl modification), Tesamorelin is priced at a premium to smaller GHRH-family analogs.
Research applications
- GHRHR agonist pharmacology on full-length GHRH analogs
- IGF-1 axis regulation and growth-hormone pulse dynamics
- Metabolic and visceral-adipose-tissue research
- Cardiovascular-endocrine research (carotid IMT, CRP)
- DPP-IV-resistant peptide design studies
Technical profile
- Net content
- 10 mg
- Molecular formula
- C221H366N72O67S
- Molecular weight
- 5136 g/mol
- CAS
- 218949-48-5
- Sequence
- Trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
For research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease. Catalog availability restricted to verified licensed practitioners.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids. It stimulates the synthesis and release of endogenous growth hormone and is researched for its effects on visceral adipose tissue reduction and lipid metabolism.
